On Monday, Japan’s Ministry of Health, Labour and Welfare announced at least nine drug approvals, five of which are products from Novartis AG (NYSE:NVS; SIX:NOVN). Two of the approvals are for HIF-PH inhibitors to treat...

DISEASE CATEGORY: Musculoskeletal INDICATION: Myotonic dystrophy type 1 (DM1) Inhibiting the transcription elongation regulator CDK12 could treat DM1, which is caused by CTG repeat expansions in the DMPK gene that result in cellular accumulation of...

Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing. The corporate venture fund...

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Adding T cell-stimulating heterologous viral vectors (HVVs) to an adjuvanted, HIV env-based HIV vaccine could improve the prevention of HIV infection. The HVVs comprise a vesicular stomatitis virus vector,...

ArcherDX picks deal with Invitae over IPO  Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus...

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...

A trio of Democrats on the House Oversight Committee are asking FDA for more information on how the agency plans to evaluate and deploy COVID-19 vaccines, in an effort to ensure the process is transparent,...

Lyell and Pact think the union of their T cell engineering technologies could overcome the roadblocks hampering cell therapies for solid tumors. While the partners are still pursuing independent pipelines, the joint program could ultimately...

CureVac and Imperial announced trial starts for their COVID-19 vaccines this week. A third vaccine, from PDS Biotech and Farmacore, is expected to start a Brazilian Phase I trial. The trial starts come as the...

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...